Abstract:Background Primary sclerosing cholangitis (PSC) is an immune-mediated cholestatic liver disease characterized by bile retention, biliary tree destruction, and progressive fibrosis leading to end stage liver disease and transplantation. There is an unmet need to understand the cellular composition of the PSC liver and how it underlies disease pathogenesis. We generated a comprehensive atlas of the PSC liver in comparison to a primary biliary cholangitis (PBC) and reference healthy liver dataset using multiple multi-omic modalities and functional validation. Methods We employed single-cell (sc) RNA-seq (47,156 cells), single-nucleus (sn) RNA-seq (23,000 nuclei) and spatial transcriptomics (1 sample by 10x Visium and 5 samples with multi-region profiling by Nanostring GeoMx Digital Spatial Profiler) to profile the cellular ecosystem in 10 patients with PSC. Transcriptomic profiles were compared to 24 neurologically deceased donor livers (107,542 cells) and spatial transcriptomics controls, 18,240 cells and 20,202 nuclei from 3 patients with PBC, and publicly available scRNA-seq data from 5 uninjured, 2 NAFLD, 2 ALD, and 1 PBC liver samples. Flow cytometry and intracellular cytokine staining was performed to validate PSC-specific differences in immune cell phenotype and function. Results PSC explants with cirrhosis of the liver parenchyma and prominent periductal fibrosis contained a population of hepatocytes expressing a cholangiocyte-like phenotype. These hepatocytes were surrounded by diverse immune cell populations, including monocyte-like macrophages, liver-resident and circulating natural killer cells. PSC-associated cholangiocytes, hepatic stellate cells, and endothelial cells expressed chemokine and cytokine transcripts typically involved in immune cell recruitment. As well, expanded CD4 + T cells, dendritic cells and neutrophils in the PSC liver expressed the corresponding receptors to these chemokines and cytokines, suggesting potential recruitment. Tissue-resident macrophages, by contrast, were reduced in number and exhibited a dysfunctional and downregulated inflammatory response to LPS and IFN-Ɣ stimulation. Conclusions We present a comprehensive atlas of the PSC liver and demonstrate hyper-activation and exhaustion-like phenotypes of myeloid cells and markers of chronic cytokine expression in late-stage PSC lesions. This atlas has the potential to expand our understanding of the cellular complexity of PSC and to inform novel treatment development. Impact and Implications Primary sclerosing cholangitis (PSC) is a rare liver disease characterized by chronic inflammation and irreparable damage to the bile ducts resulting in liver failure. Due to a limited understanding of the underlying pathogenesis of disease, there remains a paucity of treatment options. We sequenced healthy and diseased livers to compare the activity, interactions, and localization of immune and non-immune cells. This revealed that hepatocytes lining PSC scar regions are transforming into cholangiocytes, whereas immune cells are accumulating within the scars. Of these cells, macrophages, which typically contribute to tissue repair, were enriched in immunoregulatory genes and demonstrated a lack of responsiveness to stimulation. These cells may be involved in maintaining hepatic inflammation and could be targeted in novel therapeutic drug development.

Epigenetic disease markers in primary sclerosing cholangitis and primary biliary cholangitis—methylomics of cholestatic liver disease

DOP58 Human Leukocyte Antigen drives methylation signatures in primary sclerosing cholangitis but not in IgG4-related sclerosing cholangitis

DOP24 Multi-omic sequencing reveals distinctive gene expression and DNA methylation alterations as potential predictors of primary sclerosing cholangitis development in treatment-naïve paediatric Ulcerative Colitis

Evaluation of circulating cell-free DNA in cholestatic liver disease using liver-specific methylation markers

DOP80 Multi-omic sequencing reveals distinctive gene expression and DNA methylation alterations as potential predictors of primary sclerosing cholangitis development in treatment-naïve paediatric ulcerative colitis

Epigenetics of Primary Biliary Cholangitis.

Gut Pathobiont-Derived Outer Membrane Vesicles Drive Liver Inflammation and Fibrosis in Primary Sclerosing Cholangitis-Associated Inflammatory Bowel Disease

Circulating cell-free messenger RNA secretome characterization of primary sclerosing cholangitis

Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis

Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers

Single-cell and spatial transcriptomics characterisation of the immunological landscape in the healthy and PSC human liver

P327 Profiling serum metabolome and lipidome to differentiate primary sclerosing cholangitis from Inflammatory Bowel Disease and healthy controls

A Pilot Integrative Analysis of Colonic Gene Expression, Gut Microbiota, and Immune Infiltration in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Association of Disease With Bile Acid Pathways

Immunobiology of primary sclerosing cholangitis

Gene Set Enrichment Analysis Detected Immune Cell-Related Pathways Associated with Primary Sclerosing Cholangitis

Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile

A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis

Whole blood RNA sequencing identifies transcriptional differences between primary sclerosing cholangitis and ulcerative colitis

Single cell sequencing analysis identifies genetics-modulated ORMDL3+ cholangiocytes having higher metabolic effects on primary biliary cholangitis

Epigenetics of Autoimmune Liver Diseases: Current Progress and Future Directions

Comorbidities, mortality and metabolic profile in individuals with primary biliary cholangitis—A Phenome‐Wide‐Association‐Study